Members of the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) group along with experienced ...

Wedbush initiated coverage on Zenas BioPharma, Inc. (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company focused ...

Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

Baseline factors linked to SLE flares during pregnancy included thrombocytopenia and a history of LN, while antimalarial therapy demonstrated protective effects.

As previously reported, Wedbush initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $35 price target The firm notes its ...

In December 2024, the National Comprehensive Cancer Network® (NCCN) added AUCATZYL (obecabtagene autoleucel) to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and ...

Syncona Shs GBP ( ($GB:SYNC) ) has provided an announcement. Autolus Therapeutics, a portfolio company of Syncona Ltd, has announced its 2024 ...

Zenas BioPharma (ZBIO) stock rises as Wedbush issues a bullish recommendation based on the company's lead asset obexelimab. Read more here.

A new study finds that ChatGPT4 provides answers to lupus patient questions as effectively as rheumatologists, excelling in ...